Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Eisai to present new data for lenvatinib in hepatocellular carcinoma and renal cell carcinoma at ESMO 2017 Congress

Posted on: 05 Sep 17
  • Health-related quality of life analysis of Phase III data for lenvatinib vs sorafenib in unresectable hepatocellular carcinoma to be presented in an oral proffered paper session1
  • Eisai data at the congress include Phase Ib/II results of lenvatinib in combination with pembrolizumab in patients with renal cell carcinoma3


Hatfield UK, 31 August, 2017— Eisai announced today clinical trial data from their oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, being held on 8th – 12th September 2017. This will include data for lenvatinib in unresectable hepatocellular carcinoma (uHCC) and renal cell carcinoma (RCC).


An analysis of the pivotal Phase III REFLECT trial (Study 304) showing lenvatinib data on health-related quality of life and disease symptoms in patients with uHCC versus treatment with sorafenib will be presented in an oral proffered paper session on Sunday 10th September.[i] This additional information follows the results presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, which demonstrated the treatment effect of lenvatinib on overall survival by statistical confirmation by non-inferiority to sorafenib, after many failed global Phase III trials involving multiple agents studied against sorafenib in advanced HCC.[ii] For a decade there has been no new approved medication in the first-line systemic treatment of uHCC in Europe[iii],[iv]; Eisai submitted marketing authorisation to the European Medicines Agency, based on the REFLECT study.


Eisai will also present data on lenvatinib in patients with RCC, from a Phase Ib/II trial (Study 111) which evaluates the treatment of lenvatinib in combination with pembrolizumab in patients with selected solid tumours. The data show that lenvatinib in combination with pembrolizumab demonstrated promising antitumour activity and an acceptable safety profile in the RCC patient cohort.[v] The results will be presented in an oral proffered paper session on Saturday 9th September at the ESMO 2017 Congress.


The following abstracts for lenvatinib have also been accepted for presentation at the ESMO 2017 Congress:


  • Network Meta-Analysis (NMA) of Treatments for Unresectable Hepatocellular Carcinoma (uHCC)[vi]Abstract 3909: Tremblay G, et al.
    • Poster display session 707P, Hall 8
    • Saturday 9th September, 13:15 CEST
  • A Phase 2 Study of Lenvatinib Monotherapy as Second-line Treatment in Unresectable Biliary Tract Cancer: Primary Analysis Results[vii]Abstract 2304: Ikeda M, et al.
    • Poster display session 722P, Hall 8
    • Saturday 9th September, 13:15 CEST
  • Analysis of Serum Biomarkers (BM) in Patients (pts) from a Phase 3 Study of Lenvatinib (LEN) vs Sorafenib (SOR) as First-line Treatment for Unresectable Hepatocellular Carcinoma (uHCC)[viii]Abstract 3193: Finn R, et al.
    • Proffered paper session LBA30, Barcelona Auditorium
    • Sunday 10th September, 11:45 – 12:00 CEST
  • Comparing ITC Results from Lenvatinib Plus Everolimus for Second-line Treatment of Advanced/Metastatic Renal Cell Carcinoma: Crossover Versus No Crossover[ix]
    Abstract 3632: Garib S, et al.
    • Poster display session 878P, Hall 8
    • Sunday 10th September, 13:15 CEST
  • Impact of Duration of Dose Interruption on the Efficacy of Lenvatinib (LEN) in a Phase 3 Study in Patients (pts) With Radioiodine Refractory Differentiated Thyroid Cancer (RR-DTC)[x]Abstract 3074: Tahara M, et al.
    • Poster discussion session 434PD, Alicante Auditorium
    • Monday 11th September, 11:00 CEST


“Eisai is excited by the range of abstracts to be presented at this year’s congress, spanning numerous cancers that affect millions of patients across Europe. The breadth of data highlights our commitment to oncology and the discovery and development of innovative therapies from our portfolio that can make a difference and impact the lives of patients and their families. Our passion for people is part of our human health care (hhc) mission, which strives to better understand the needs of patients and their families to increase the benefits health care provides,” commented Gary Hendler, Chairman & CEO EMEA, Chief Commercial Officer, Oncology Business Group at Eisai.

Editor's Details

Mike Wood

Last updated on: 05/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.